Tobi Podhaler is an antibiotic used to treat an infection caused by the bacteria Pseudomonas aeruginosa in people who have cystic fibrosis. This prescription medicine comes as a capsule that is used in a certain device that allows you to inhale the powder inside the capsules. It is used twice daily. Side effects include sore throat, shortness of breath, and coughing.
Tobi® Podhaler™ (tobramycin inhalation powder) is a prescription medication approved to treat people with cystic fibrosis who have an infection with a bacteria known as Pseudomonas aeruginosa. It belongs to a group of medicines known as aminoglycoside antibiotics.
Tobi Podhaler is made by Novartis Pharmaceuticals Corporation.
Tobi Podhaler contains the antibiotic tobramycin. It works by killing bacteria. The drug does this by interfering with the bacteria's ability to make proteins, which are necessary for the bacteria to grow and multiply.
Tobi Podhaler has been studied in clinical trials that included people with cystic fibrosis who had the bacteria P. aeruginosa in their lungs. In one study, Tobi Podhaler improved lung function more so than the placebo (an inhaled "medicine" with no active ingredients).
The drug also reduced the need for hospitalization and additional antibiotics. More specifically, 4.4 percent of people given Tobi Podhaler needed to be hospitalized, and 8.7 percent required additional antibiotics for their infection. In comparison, of those given the placebo, 12.2 percent needed to be hospitalized and 10.2 percent needed additional antibiotics.